Skip to main content
Toggle navigation
Login
Search
Home
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Favorite
Tweet this
Print
Brendan Eckelman, PhD
Inhibrx, Inc
Poster(s):
(P 041) UPDATED EFFICACY AND SAFETY OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109 IN PATIENTS WITH CHONDROSARCOMA: DATA FROM THE PHASE 1 EXPANSION COHORTS
(P 315) A RANDOMIZED, PLACEBO-CONTROLLED, PHASE 2 TRIAL OF INBRX-109 IN UNRESECTABLE OR METASTATIC CONVENTIONAL CHONDROSARCOMA
(P 317) INBRX-109 IN EWING SARCOMA: PRECLINICAL RATIONALE FOR INITIATION OF A PHASE 1 CHEMOTHERAPY COMBINATION EXPANSION COHORT
